

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Meyers, Rachel E. et al.

Application No.: TBA

Group No.: TBA

Filed: Herewith

Examiner: TBA

For: 32544, A NOVEL HUMAN PHOSPHOLIPASE C AND USES THEREOF

Mail Stop Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

**List of Sections Forming Part of This Information Disclosure Statement**

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) (3 pages)
- 3.. ☒ Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

- ☐ with sufficient postage as first class mail.

- ☒ as "Express Mail Post Office to Addressee"  
Mailing Label No. EV439625533US

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

  
Signature

Date: February 20, 2004

Sean Hunziker

(type or print name of person certifying)

**Preliminary Statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.


**Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted**

This application relies, under 35 U.S.C. section 120, on the earlier filing date of prior application Serial No.: 09/ 927,112, filed on August 10, 2001.

The following references were submitted to, and/or cited by, the Office in the prior application(s) and, therefore, are not required to be provided in this application. However, in the event additional copies are necessary, the undersigned will submit such copies upon request.

February 20, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By   
Tracy M. Sioussat  
Registration No. 50,609  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone – (617) 374-7679  
Facsimile – (617) 551-8820

Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p>				<b>Complete if Known</b>	
				Application Number	TBA
				Filing Date	Herewith
				First Named Inventor	Meyers, Rachel E., et al.
				Group Art Unit	TBA
				Examiner Name	TBA
				Attorney Docket Number	MPI00-456P1RDV1M
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Kind Code <sup>2</sup> Number (if known)				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	B1	WO	02/04490	A2	Incyte Genomics, Inc.	01-17-2002	Pages 1-108 specification, Sequence Listing pages 3-4, 14-15	
	B2	WO	01/85956	A2	Incyte Genomics, inc.	11-15-2001	Pages 1-104 specification, Sequence Listing pages 9-11, 16-17, 9 pages International Search Report	
	B3	WO	02/063005	A2	Incyte Genomics, Inc.	08-15-2002	Pages 1-122 specification, Sequence Listing pages 13-16, 27-28	
	B4	WO	02/16597	A2	Incyte Genomics, Inc.	02-28-2002	Pages 1-106, Sequence Listing pages 6-10, 13-15	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	TBA		
		Filing Date	Herewith		
		First Named Inventor	Meyers, Rachel E. et al.		
		Group Art Unit	TBA		
		Examiner Name	TBA		
Sheet	1	of	1	Attorney Docket Number	MPI00-456P1RDV1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T <sup>2</sup>
	C1	DATABASE EMBL 'Online! 13 August 1998 (1998-08-13), retrieved from EBI Database Accession No. AB007919, XP002220767	
	C2	Seki, N., et al., "Characterization of cDNA Clones in Size-Fractionated cDNA Libraries from Human Brain", <i>DNA Research</i> , Vol. 4, September 19, 1997, pp:345-349, XP000870411 *whole document*	
	C3	DATABASE EMBL 'Online! 1 May 2000 (2000-05-01), retrieved from EBI Database Accession No. Q9UPT3, XP002220768	
	C4	Reiko, K., et al., Prediction of the Coding Sequences of Unidentified Human Genes. XIV. The Complete Sequences of 100 new cDNA Clones from Brain Which Code for Large Proteins <i>in vitro</i> ", <i>DNA Research</i> , Vol. 6, May 31, 1999, pp:197-205, XP000852618 *whole document*	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.